Iron Deficiency Anemia - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Iron Deficiency Anemia - Pipeline Review, H1 2019’, provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia

- The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects

- The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akebia Therapeutics Inc

Iron4u Aps

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma ...

Akebia Therapeutics Inc

Iron4u Aps

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Iron Deficiency Anemia - Overview

Iron Deficiency Anemia - Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Iron Deficiency Anemia - Overview

Iron Deficiency Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Iron Deficiency Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iron Deficiency Anemia - Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Iron4u Aps

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma Ltd

Iron Deficiency Anemia - Drug Profiles

AKB-5343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSJ-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ferric bepectate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric maltol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric pyrophosphate citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hinokitiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iron isomaltoside - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-30 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iron Deficiency Anemia - Dormant Projects

Iron Deficiency Anemia - Product Development Milestones

Featured News & Press Releases

Jan 29, 2019: Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru

Jan 24, 2019: Shield Therapeutics: Business and trading update

Dec 13, 2018: Shield Therapeutics announces the US new drug application PDUFA date for Feraccru

Dec 10, 2018: Rockwell Medical appoints new Vice President, Operations

Dec 06, 2018: Clinical trial sheds new light on potential risk associated with intravenous iron treatment

Dec 05, 2018: Shield Therapeutics notes UK launch of Feraccru by Norgine

Dec 04, 2018: New study demonstrates significant difference between Iron Isomaltoside and Ferric Carboxymaltose on hypophosphatemic effects in a controlled, randomized clinical investigation

Dec 03, 2018: Shield Therapeutics announces the new drug application for Feraccru has been accepted for filing and review by the FDA

Oct 12, 2018: Rockwell Medical provides update on IV Triferic

Oct 01, 2018: Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru for the treatment of iron deficiency with the US Food and Drug Administration (FDA)

Sep 13, 2018: Shield reports completion of recruitment to AEGIS Head to Head Study (AEGIS-H2H) comparing Feraccru with ferric carboxymaltose

Sep 06, 2018: Monoferric receives marketing approval from Health Canada

Jun 28, 2018: Shield Reports Recently Presented Supportive Data from Real-world Clinical use of Feraccru (Ferric Maltol)

Jun 14, 2018: Shield reports positive top-line results from its AEGIS-PAED PK Paediatric Phase I Pharmacokinetics study of Feraccru (Ferric Maltol) in subjects with iron deficiency

May 02, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 International Congress on Peritoneal Dialysis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, H1 2019

Iron Deficiency Anemia - Pipeline by Iron4u Aps, H1 2019

Iron Deficiency Anemia - Pipeline by Novartis AG, H1 2019

Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H1 2019

Iron Deficiency Anemia - Pipeline by Pharmacosmos AS, H1 2019

Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals Inc, H1 2019

Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, H1 2019

Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H1 2019

Iron Deficiency Anemia - Pipeline by Vifor Pharma Ltd, H1 2019

Iron Deficiency Anemia - Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports